Season 13 · Episode 15
S13 Ep15: The Expanding Role of AR Inhibition in mHSPC Management: With Alicia Morgans, MD, MPH
OncLive® On Air · OncLive® On Air
June 16, 202511m 25s
Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In our exclusive interview, Dr Morgans detailed the evolving role of AR inhibitors in the mHSPC setting, including the recent expanded approval for darolutamide (Nubeqa) for this population. She discussed treatment considerations for determining whether to give docetaxel along with darolutamide; other factors to remember with AR inhibition; and the need to continue driving consensus across practices in the management of prostate cancer.